

Partnering with WARPNINE

WARPNINE 2026 Research & Impact

Accelerating Cancer Research.
Creating Better Possibilities
for Patients.

warpnine.org.au

A Note from Our CEO

AUGUST 2026

WARPNINE was established in 2021 with a simple but ambitious vision: to accelerate research with the potential to improve outcomes for patients facing pancreatic, upper gastrointestinal and rare cancers.

Too often, promising research stalls—not because the science lacks merit, but because the funding, dedicated capacity, coordination or infrastructure needed to progress it is unavailable. WARPNINE was created to help bridge that gap by combining targeted philanthropic investment with the practical leadership and research support required to move discoveries from concept to clinical trial—and ultimately from bench to bedside.

Our approach extends beyond funding. We bring together clinicians, researchers, hospitals, industry and philanthropic partners; invest in dedicated research fellowships; help navigate governance and development pathways; and, where appropriate, accept the significant responsibility of clinical sponsorship.

This model allows us to respond quickly to emerging opportunities and support innovative research at the point it needs us most. It also creates a multiplying effect: one well-supported project can generate new evidence, collaborations, intellectual property and further research opportunities.

In just five years, the generosity of our supporters has enabled WARPNINE to advance pioneering clinical trials, invest in emerging clinician-researchers and develop a growing portfolio of patient-focused research. Every project within this prospectus reflects our commitment to backing exceptional people with promising ideas—and helping translate scientific potential into meaningful outcomes for patients and their families.

The opportunities presented here demonstrate both the breadth of our work and the potential for far greater impact. Through continued partnership, WARPNINE can accelerate high-potential research that may otherwise be delayed, underfunded or remain unexplored.

Thank you for taking the time to learn more about WARPNINE, the progress already achieved and the opportunities ahead. We invite individuals, families, foundations and organisations who share our determination to change what is possible for patients to partner with us.

Warm regards,

Meg Croucher
Chief Executive Officer
WARPNINE

Why WARPNINE?

We fund what can't wait.

Every year, promising research ideas fail to progress—not because they lack scientific merit, but because funding isn't available at the point it is needed most.

Traditional grant funding is highly competitive and often takes months—or even years—to secure. For patients facing aggressive cancers, time is a luxury they simply don't have.

WARPNINE exists to bridge this gap by providing strategic philanthropic investment that enables researchers to generate the evidence needed to progress clinical trials, attract larger funding, and ultimately improve patient outcomes.

We don't replace traditional research funding—we help researchers get there sooner.

We invest in people with great ideas.

Our focus is on investigator-led clinical trials, translational research and research fellowships with the potential to make a meaningful difference for patients.

Rather than funding research for the sake of research, we back exceptional clinicians and researchers with innovative ideas and a clear pathway to improving patient care.


By supporting the right people at the right time, philanthropy can accelerate discoveries that may otherwise never progress.

We create impact beyond every dollar invested.

Every philanthropic investment is designed to do more than fund a single project.

By supporting early-stage research, pilot studies and investigator-led clinical trials, WARPNINE helps generate the evidence required to attract larger competitive grants, establish new collaborations and build sustainable research programs.

The result is an investment that continues to deliver value long after the original gift has been made.



Five Years of Impact

Accelerating research. Creating opportunities. Changing lives

Since 2021, WARPINE has invested in investigator-led clinical trials, translational research and research fellowships that are accelerating better treatments for patients facing pancreatic, gastro-intestinal and rare cancers.

Every philanthropic investment is focused on accelerating the journey from scientific discovery to improved patient outcomes.



5

YEARS OF
IMPACT



10+

RESEARCH PROJECTS
SUPPORTED



3

RESEARCH FELLOWSHIPS
SUPPORTED



100+

PATIENTS INVOLVED IN
WARPINE-SUPPORTED
RESEARCH



\$1M+

INVESTED INTO CANCER
RESEARCH



8

INTERNATIONAL
CONFERENCE
PRESENTATIONS

Research Highlights



CLINICAL TRIALS

- ✓ 100% of evaluable patients experienced tumour shrinkage*
- ✓ Nine patients became eligible for surgery following treatment
- ✓ Findings presented internationally at ESMO GI 2026

Based on preliminary iLSTA Phase 1b/2a data presented at ESMO GI 2026.



TRANSLATIONAL RESEARCH

- ✓ Identification of immune and microbiome signatures associated with treatment response
- ✓ Advancing personalised approaches to cancer treatment
- ✓ Building the evidence for future therapeutic strategies



RESEARCH FELLOWSHIPS

- ✓ Supporting the next generation of clinician-researchers
- ✓ Building research capacity in Western Australia
- ✓ Accelerating investigator-led clinical research



CATALYSING RESEARCH

- ✓ Early philanthropic investment helping unlock larger research collaborations
- ✓ Supporting pilot data to strengthen competitive grant applications
- ✓ Creating lasting impact beyond the initial investment

Research Fellowship Program

Investing in People. Accelerating Discovery.

Behind every clinical trial, every research breakthrough and every new treatment is a researcher asking an important question.

At WARPnine, we believe one of the greatest investments philanthropy can make is in the people driving those discoveries.

Our Research Fellowship Program supports talented early-career researchers and clinician-researchers to pursue innovative ideas, generate critical evidence and build the skills, collaborations and experience needed to become the next generation of research leaders.

By providing protected research time and dedicated project support, philanthropic investment enables fellows to accelerate research that has the potential to improve outcomes for patients facing pancreatic, gastro-intestinal and rare cancers.

WHY IT MATTERS



ACCELERATES RESEARCH

Supports dedicated research time so promising ideas can progress faster.



BUILDS FUTURE LEADERS

Develops the next generation of clinician-researchers in Western Australia.



CREATES LASTING IMPACT

Investment in one fellow creates benefits across multiple projects, collaborations and future grants.

CURRENT WARPnine RESEARCH FELLOWS



OLIVIA COMITO RESEARCH FELLOW

Leading translational microbiome research across multiple investigator-led clinical trials.



DR MACLAIN ROBINSON ACCELERATOR RESEARCH FELLOW

Advancing clinical research concepts, translational studies and collaborative research programs.



Supporting researchers is one of the most effective ways philanthropy can accelerate better treatments for future patients.

Dr Andrew Dean
Founder & Chairman WARPnine



Investment in our Research Fellowship Program creates the dedicated capacity needed to advance promising research, pursue emerging discoveries and translate findings into better outcomes for patients.



Partnership Opportunity

We welcome partnerships with individuals, families, foundations and organisations seeking to accelerate patient-focused cancer research. Support can be directed towards a specific Research Fellow, the broader Fellowship Program or an area of greatest need.

POGO-STICK

Creating a lasting research resource to advance personalised cancer care.

Why do some patients respond remarkably well to treatment while others do not?

Researchers increasingly believe that part of the answer may lie within the microbiome—the trillions of microorganisms that naturally live within our bodies.

POGO-STICK is a new investigator-led research platform designed to better understand how the microbiome influences treatment response, treatment-related toxicity and long-term outcomes across multiple upper gastrointestinal cancers.

Unlike many research studies that answer a single question, POGO-STICK is being established as an enduring research resource, creating a platform that can support future clinical trials, translational research and collaborative projects for years to come.

WHY IT MATTERS



CREATES A LASTING RESEARCH RESOURCE

A longitudinal collection of microbiome samples linked with clinical and treatment data.



SUPPORTS FUTURE RESEARCH

A platform designed to support future investigator-led studies.



ADVANCES PERSONALISED MEDICINE

Helping researchers understand why patients respond differently to treatment.

STUDY OVERVIEW



50

PARTICIPANTS

Initial recruitment cohort.



5

CANCER STREAMS

pancreatic, oesophageal, gastro-oesophageal junction, stomach, and biliary cancer.



3

COLLECTION TIMEPOINTS

Baseline, during and post-treatment.



INTEGRATED CLINICAL DATA

Treatment response and outcomes.



FUTURE

RESEARCH PLATFORM

Future studies and collaborations.

How Your Support Can Help



POGO-STICK is more than a single research study. It is being established as a long-term research platform that future researchers can continue to build upon.

Philanthropic support will help establish the platform through participant recruitment, sample collection, laboratory analysis and data integration—creating a lasting resource capable of supporting future discoveries.

CPET

Understanding how cancer treatment affects the people receiving it.

Not every patient responds to cancer treatment in the same way.

While modern treatments have significantly improved outcomes, they can also have a profound impact on a patient's physical fitness and ability to tolerate ongoing treatment.

Cardiopulmonary Exercise Testing (CPET) provides an objective assessment of a patient's exercise capacity before, during and after treatment. By measuring how physical function changes over time, researchers hope to better understand its relationship with treatment tolerance, recovery and long-term outcomes.

WARPNINE is supporting a prospective multicentre research program that will be among the first in Australia to prospectively evaluate these changes in patients undergoing treatment for gastric and oesophageal cancers.

WHY IT MATTERS



UNDERSTANDING TREATMENT IMPACT

Measuring how cancer treatment affects physical function over time.



INFORMING CLINICAL DECISIONS

Generating evidence to better understand treatment tolerance and recovery.



IMPROVING FUTURE CARE

Helping shape future approaches to personalised cancer care.

STUDY OVERVIEW



60

PARTICIPANTS

Prospective multicentre observational study.



3

ASSESSMENT TIMEPOINTS

Before treatment, during treatment and following surgery (where applicable).



CPET ASSESSMENT

Standardised cardiopulmonary exercise testing



CLINICAL OUTCOMES

Exercise capacity analysed alongside treatment outcomes.



FUTURE RESEARCH

Creating evidence to inform future clinical practice and intervention studies.

How Your Support Can Help



Philanthropic support will help establish this important research program by funding CPET assessments, research coordination and data collection.

By better understanding how cancer treatment affects physical function, this research has the potential to inform future clinical practice, support more personalised care and improve outcomes for patients facing gastric and oesophageal cancers.

Cholangiocarcinoma ctDNA

A simple blood test with the potential to transform cancer monitoring.

Even after successful surgery, cholangiocarcinoma carries a high risk of recurrence.

Today, patients are monitored using imaging such as CT and MRI scans together with blood tests. While effective, these approaches can be expensive, may not detect recurrence at its earliest stages and can be difficult to access for patients living in regional and remote areas.

Researchers are developing a new methylation-based blood test designed to detect tiny amounts of circulating tumour DNA (ctDNA), with the potential to identify residual disease and cancer recurrence earlier than conventional surveillance methods.

Building on promising proof-of-concept work in liver cancer, this project aims to adapt the technology for cholangiocarcinoma and lay the foundation for a simpler, more accessible approach to cancer monitoring.

WHY IT MATTERS



EARLIER DETECTION

Earlier identification of cancer recurrence.



SIMPLER MONITORING

A simple blood test to complement existing surveillance.



BETTER ACCESS

Making cancer monitoring simpler and more accessible for patients.

PROJECT PATHWAY



EXISTING PROOF OF CONCEPT

Technology already demonstrated in liver cancer.



ASSAY DEVELOPMENT

Adapting the technology for cholangiocarcinoma.



CLINICAL VALIDATION

Testing stored and prospective patient samples.



TRANSLATIONAL DEVELOPMENT

Funding specialised laboratory consumables and sequencing.



FUTURE CLINICAL APPLICATION

Laying the foundation for a new approach to monitoring recurrence.

Partnership Opportunity



Philanthropic support will directly fund the laboratory work required to develop and validate this promising technology.

Funding for specialised sequencing, DNA methylation analysis and laboratory consumables will help generate the evidence needed to advance a simpler, more accessible approach to monitoring patients with cholangiocarcinoma after treatment.

Partnering with WARPnine

Every breakthrough begins with the courage to believe that something better is possible.

WARPnine's progress has been made possible through a shared determination to improve outcomes for people facing pancreatic, upper gastrointestinal and rare cancers.

Partnership enables us to act when promising research needs more than funding alone. It provides the capacity to advance new ideas, support dedicated researchers, bring together the right expertise and move discoveries closer to patients.

Individuals, families, foundations and organisations can partner with WARPnine by supporting a Research Fellowship, a specific research project or an area of greatest need. Every partnership is shaped by a common purpose: to accelerate meaningful, patient-focused research and create new possibilities where they are urgently needed.

Thank you for taking the time to learn more about WARPnine, the progress we have achieved and the opportunities ahead. We welcome the opportunity to work with those who share our belief that better outcomes are possible—and are ready to help make them happen.



Meg Croucher

Chief Executive Officer
WARPnine

admin@warpline.org.au
www.warpline.org.au



Together, we can accelerate research and change what is possible for patients.

The WARPnine logo, consisting of the word 'WARPnine' in a bold, sans-serif font, is printed on the back of a black t-shirt worn by a person sitting on a beach at sunset. The person is seen from behind, along with three other people (two children and one adult) sitting next to them, all looking out at the ocean. The background is a warm sunset scene with orange and yellow light reflecting on the water and sand.